TAK-875 Improves Glycemic Control in Type 2 Diabetes
Targeting of free fatty acid receptor 1 beneficial for patients unresponsive to diet or metformin
MONDAY, Feb. 27 (HealthDay News) -- For patients with type 2 diabetes who do not respond to diet or metformin treatment, selective pharmacological activation of the free fatty acid receptor 1 (FFAR1) by TAK-875 improves glycemic control, according to a phase 2 study published online Feb. 27 in The Lancet.
Charles F. Burant, M.D., from the University of Michigan in Ann Arbor, and colleagues randomly assigned 426 patients with type 2 diabetes who had not responded to diet or metformin treatment to receive TAK-875 (303 patients), placebo (61), or glimepiride (62) for 12 weeks.
The researchers found that, at week 12, there were significant least-squares mean reductions in hemoglobin A1c from baseline in all patients in the TAK-875 and glimepiride groups compared with placebo. For TAK-875 and placebo, the treatment-emergent hypoglycemic events rates were similar (2 and 3 percent, respectively), but the rate was significantly higher in the glimepiride group (19 percent). There was a similar incidence of treatment-emergent adverse events in the TAK-875 and placebo groups (49 and 48 percent, respectively), but more events were seen in the glimepiride group (61 percent).
"TAK-875 significantly improved glycemic control in patients with type 2 diabetes with minimum risk of hypoglycemia. The results show that activation of FFAR1 is a viable therapeutic target for treatment of type 2 diabetes," the authors write.
All of the authors disclosed ties to Takeda Global Research and Development, which funded the study and manufactures TAK-875.